These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12522440)

  • 21. Local delivery of poxvirus vaccines for melanoma.
    Hörig H; Kaufman HL
    Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
    Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
    Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
    Bitzer M; Lauer UM
    Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
    Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
    J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technology evaluation: anticancer gene therapy, MediGene.
    Hunt S
    Curr Opin Mol Ther; 2001 Oct; 3(5):509-14. PubMed ID: 11699897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular strategies for improving cytokine transgene expression in normal and malignant tissues.
    Yang NS; Wang JH; Turner J
    Gene Ther; 2004 Jan; 11(1):100-8. PubMed ID: 14681703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenoviral strategies for the gene therapy of cancer.
    Relph KL; Harrington KJ; Pandha H
    Semin Oncol; 2005 Dec; 32(6):573-82. PubMed ID: 16338423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenoviral vectors: systemic delivery and tumor targeting.
    Green NK; Seymour LW
    Cancer Gene Ther; 2002 Dec; 9(12):1036-42. PubMed ID: 12522442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
    Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
    J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A balance of clinical trials in gene therapy].
    Favrot MC; Coll JL; Puisieux I
    Bull Cancer; 1999 Jan; 86(1):115-21. PubMed ID: 10029714
    [No Abstract]   [Full Text] [Related]  

  • 31. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of cancer by cytokines mediated by gene therapy approach.
    Qian C; Liu XY; Prieto J
    Cell Res; 2006 Feb; 16(2):182-8. PubMed ID: 16474432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma.
    Finocchiaro LM; Fiszman GL; Karara AL; Glikin GC
    Cancer Gene Ther; 2008 Mar; 15(3):165-72. PubMed ID: 18219342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
    Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules.
    Kaufman HL
    Ann N Y Acad Sci; 2005 Dec; 1062():41-50. PubMed ID: 16461787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.